11 Worst Performing Stocks in S&P 500 So Far in 2025

7. Moderna, Inc. (NASDAQ:MRNA)

YTD Decline in Share Price: -35.19%

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company renowned for its groundbreaking mRNA technology and expertise in developing vaccines and therapeutics for complex diseases.

The company made a name for itself by quickly developing an effective coronavirus vaccine when the world needed it the most. However, the stock has largely struggled since the pandemic started to recede. Moderna, Inc. (NASDAQ:MRNA)’s weak financial performance has also hurt investor sentiment.

The company reported a revenue of $3.2 billion for the fiscal year 2024, down 53% from the prior year due to lower product sales. Net loss for the year was posted at $3.6 billion, with a loss per share of $9.28. The company expects revenue for fiscal 2025 to be further down, in the range of $1.5 billion to $2.5 billion, with a major chunk expected during the second half of the year.

Moderna, Inc. (NASDAQ:MRNA) is also grappling with the challenges of a volatile political environment, with reports about the Trump administration deciding to reevaluate a $590 million contract awarded to the company for a bird flu vaccine by the Biden administration in January this year. The stock has also suffered due to the recent resignation of the FDA’s vaccine chief, Peter Marks, who oversaw the development of several COVID-19 vaccines.

With a year-to-date slump of over 35%, Moderna, Inc. (NASDAQ:MRNA) is among the worst performing stocks so far in 2025. While analysts have a consensus Hold rating for the stock, it has an impressive share price upside potential of 98%, with anticipation of a recovery at some point ahead as the company makes clinical progress on certain treatments.